Mitochondrial Transplantation Ameliorates The Development and Progression of Osteoarthritis.

A Ram Lee  
Catholic University of Korea School of Medicine

Jin Seok Woo  
Catholic University of Korea School of Medicine

Seon-Yeong Lee  
Catholic University of Korea School of Medicine

Hyun Sik Na  
Catholic University of Korea School of Medicine

Keun-Hyung Cho  
Catholic University of Korea School of Medicine

Yeon Su Lee  
Catholic University of Korea School of Medicine

Jeong Su Lee  
Catholic University of Korea School of Medicine

Seon Ae Kim  
Catholic University of Korea School of Medicine

Sung-Hwan Park  
Catholic University of Korea School of Medicine

Seok Jung Kim  
Catholic University of Korea School of Medicine

Mi-La Cho  
Catholic University of Korea College of Medicine: Catholic University of Korea School of Medicine  
iammila@catholic.ac.kr

Research

Keywords: Osteoarthritis, Mitochondrial transplantation, Autophagy, Inflammatory Cell Death

Posted Date: July 22nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-704990/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Objective: Osteoarthritis (OA) is a common degenerative joint disease characterized by breakdown of joint cartilage. Mitochondrial dysfunction of the chondrocyte is a risk factor for OA progression. We examined the therapeutic potential of mitochondrial transplantation for OA.

Methods: Mitochondria were injected into the knee joint of monosodium iodoacetate (MIA)-induced OA rats. Chondrocytes from OA rats or patients with OA were cultured to examine mitochondrial function in cellular pathophysiology.

Results: Pain, cartilage destruction, and bone loss were improved in mitochondrial transplanted-OA rats. The transcript levels of interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), matrix metallopeptidase 13 (MMP13), and monocyte chemoattractant protein-1 (MCP-1) in cartilage were markedly decreased by mitochondrial transplantation. Mitochondrial function, as indicated by membrane potential and oxygen consumption rate, in chondrocytes from OA rats was improved by mitochondrial transplantation. Likewise, the mitochondrial function of chondrocytes from OA patients was improved by coculture with mitochondria. Furthermore, inflammatory cell death was significantly decreased by coculture with mitochondria.

Conclusion: Mitochondrial transplantation ameliorated OA progression, which is caused by mitochondrial dysfunction. These results suggest the therapeutic potential of mitochondrial transplantation for OA.

Introduction

Osteoarthritis (OA) is a common degenerative joint disease that results from breakdown of joint cartilage and underlying bone. OA is characterized by the infiltration of immune cells into cartilage and cartilage destruction (1, 2). The risk factors for OA include joint injury, age, obesity, and gender, and it causes pain, stiffness, bone spurs, and swelling (3, 4). Although OA does not affect life expectancy, it significantly disrupts the quality of life. Drug treatment is focused on pain relief, not on the progression of OA.

Mitochondria are complex and dynamic organelles, whose main function is energy production for the maintenance of cellular homeostasis (5). The number of mitochondria depends on cell type, and they typically occupy ~ 20% of the cell volume (6). Chondrocytes are the only cell type in healthy cartilage (7). Recent studies have reported mitochondrial dysfunction, including mitochondrial respiratory chain enzyme complex activities and membrane potential, in chondrocytes of OA patients (8). Mitochondrial dysfunction leads to cartilage degeneration by suppressing adenosine triphosphate (ATP) production, depolarizing the mitochondrial membrane, increasing oxidative stress, disrupting calcium homeostasis, and altering mitochondrial DNA (mtDNA) (9-12). Mitochondrial dysfunction has been reported in OA chondrocytes, inducing an imbalance between anabolism and catabolism of extracellular matrix (13, 14) and decreasing mitochondrial complex activity (15, 16).
Autophagy is a self-degradative cellular and molecular mechanism that removes dysfunctional or unnecessary proteins and organelles (17). The OA environment increases reactive oxygen species (ROS) levels, impeding autophagolysosome progression via mitochondrial and lysosomal dysfunction (18). Accumulation of autophagosomes caused by lysosomal dysfunction promotes OA progression and activation of lysosomal function by metformin ameliorates OA progression (19).

Mitochondrial transplantation has been proposed to be a novel therapeutic intervention for heart injury, kidney injury, neurodegenerative diseases, and cancer (20-24). Mitochondrial transplantation enhances ATP synthesis, oxygen consumption, and cell viability, thereby improving systemic function. Also, mitochondrial transplantation has immunomodulatory effects in the sepsis mouse model (25).

Based on the above, mitochondrial transplantation is being investigated as a therapeutic target for many diseases, but not in OA. We examined the therapeutic potential of mitochondrial transplantation for OA and observed that mitochondrial transplantation ameliorates OA progression. Inflammatory cell death and autophagy were improved by mitochondrial transplantation. Our findings demonstrate for the first time the therapeutic potential of mitochondrial transplantation for OA.

Materials And Methods

Induction of OA in rat

Male Wistar rats (180–250 g, 7 weeks of age) were purchased from Central Lab Animal Inc. (Seoul, South Korea). Animals were randomly assigned to the treatment or control group before the study began. After anesthetization with isoflurane, seven-week-old male Wistar rats (n = 5) were injected with 3 mg of monosodium iodoacetate (MIA; I2512, Sigma, St. Louis, MO), dissolved in a 50 μL of saline, using a 26.5 G needle inserted through the patellar ligament into the intra-articular space of the right knee. Mitochondria were administered to 10 μg/50 μL volume twice weekly in the right knee intra-articular space of monosodium iodoacetate (MIA)-induced rats, and rats in the control group were injected with the same volume of saline.

Isolation of mitochondria from L6 cells and human muscle

Mitochondria were isolated from L6 rat cells using a Mitochondrial Isolation Kit for Cultured Cells (89874, Thermo, MA). Briefly, $3 \times 10^6$ L6 cells were incubated with 400 μL of reagent A for 2 min on ice with vortexing every minute and incubated with 5 μL of reagent B for 5 min on ice. After adding 400 μL of reagent C, cells were centrifuged at 700 g for 10 min at 4°C. The supernatant was transferred to a new tube and centrifuged at 12,000 g for 15 min at 4°C. The pellet (mitochondria) was washed with 400 μL of reagent C and centrifuged at 12,000 g for 5 min at 4°C. Mitochondria from muscle tissue of OA patients were isolated according to Boutagy et al. (46). Protein concentrations were quantified by bicinchoninic acid (BCA) assay (23235, Thermo).

Rat and human articular chondrocyte differentiation and culture
Chondrocytes were isolated from the cartilage of MIA-induced OA rats and patients. Cartilage was digested with 0.5 mg/mL hyaluronidase, 5 mg/mL protease type I, and 2 mg/mL collagenase type V. Chondrocytes were incubated Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum. Rat chondrocytes of passage 1 were cultured and analyzed. Human chondrocytes were cultured in the presence or absence of IL-1β (20 ng/mL) and 5 μg of isolated mitochondria for 24 h.

**Assessment of pain behavior**

Nociception in MIA-treated rats was tested using a dynamic plantar aesthesiometer (Ugo Basile, Gemonio, Italy). The device is an automated version of the von Frey hair assessment procedure and is used to assess mechanical sensitivity. When the instrument was activated, a fine plastic monofilament advanced at a constant speed and touched the paw in the proximal metatarsal region. The filament exerted a gradually increasing force on the plantar surface, starting below the threshold of detection and increasing until the stimulus became painful, as indicated by the rat’s withdrawal of its paw. The force required to elicit a paw-withdrawal reflex was recorded automatically and measured in g. A maximum force of 50 g and a ramp speed of 25 s were used for all aesthesiometer tests. Weight balance in MIA-treated rats was analyzed using an incapacity meter (IITC Life Science, CA). The rats were allowed to acclimate for 5 min in an acrylic holder. After 5 min, both feet of the rat were fixed to the pad and the weight balance was measured for 5 s. Three measurements were repeated in the same manner. The weight of the unguided and guided legs was determined and substituted in the formula to calculate the percentage. The percentage value was calculating by comparing the legs with and without osteoarthritis.

**Histopathological analysis**

Knee joints were collected from each group 3 weeks after MIA induction. The tissues were fixed in 10% formalin after decalcification using Decalcifying Solution-Lite (Sigma, St. Louis, MO), and embedded in paraffin. Tissue was stained with hematoxylin and eosin (H&E) and safranin O and analyzed by the Osteoarthritis Research Society International (OARSI) and the Mankin scoring system (26).

**Immunohistochemistry**

Paraffin-embedded sections were incubated at 4°C with the following primary monoclonal antibodies: anti-IL-1β (ab9722, Abcam, Cambridge, UK), anti-TNF-α (ab6671, Abcam), anti-MMP13 (ab39012, Abcam), anti-MCP-1 (ab7202, Abcam) and anti-phospho-mixed lineage kinase domain-like protein (ab196436, Abcam). The samples were next incubated with the respective secondary biotinylated antibodies, followed by incubation for 30 min with streptavidin–peroxidase complex. The reaction product was developed using 3,3-diaminobenzidine chromogen (K3468, Dako, CA).

**In vivo micro-computed tomography**

Micro-computed tomography (CT) was performed using a bench-top cone-beam type *in vivo* animal scanner (mCT 35; SCANCO Medical, Wangen-Brüttisellen, Switzerland). The animals were imaged at settings of 70 kVp and 141 μA using a 0.5-mm-thick aluminum filter. The pixel size was 8.0 μm and the
rotation step was 0.4°. Cross-sectional images were reconstructed using a filtered back-projection algorithm (NRecon software, Bruker micro CT, Belgium). For each scan, a stack of 286 cross-sections was reconstructed at 2,000 × 1,335 pixels. Bone volume and surface were analyzed at the femur.

**Electron microscopy**

Cells were fixed in 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer overnight at 4°C. The cells were washed in 0.1 M phosphate buffer, postfixed with 1% osmium tetroxide for 1 h at 4°C, dehydrated in graded ethyl alcohol solutions, exchanged in acetone, and embedded in Epon 812. Ultrathin sections (70–80 nm) were obtained on an ultramicrotome (Leica Ultracut, Leica, Vienna, Austria) and stained with uranyl acetate and lead citrate. Images were acquired at 60 kV using a transmission electron microscope (JEM 1010, JEOL, Tokyo, Japan).

**CTX-II enzyme-linked immunosorbent assay**

CTX-II level from the serum of MIA-induced OA model was performed based on the method of the CTX-II (E-EL-R2554, Elabscience, TX) kit.

**ATP assay**

Isolated mitochondrial ATP content was analyzed using the ATP Lite Luminescence Assay System (6016943, Perkin Elmer, UK)

**Coculture of osteoarthritic human chondrocytes with mitochondria**

OA chondrocytes were seeded in 24-well plates at 5 × 10⁴/well with isolated mitochondria (5 μg) in 10% DMEM. One day later, the cell culture medium was replaced with 0.1% insulin–transferrin–selenium-A (ITSA)–DMEM, and isolated mitochondria were layered onto the OA chondrocytes. Cells were incubated at 37°C for 24 h and harvested for further experiments.

**Mitochondrial analysis by flow cytometry**

Delivery of exogenous mitochondria to human chondrocytes was confirmed by Mitotracker deep red (M22426, Thermo) staining. The mitochondrial membrane potential was measured by JC-1 (T3168, Thermo) staining. The mitochondrial ROS level was measured by MitoSOX (M36008, Thermo) staining, and analyzed by flow cytometry on a FACS Calibur instrument (BD Biosciences).

**Annexin V and propidium-iodide staining**

Chondrocytes were harvested and stained with fluorescein isothiocyanate-conjugated Annexin V and propidium iodide (K101-100, BD Biosciences) for 5 min at room temperature. Flow cytometric analysis was performed on a FACS Calibur instrument (BD Biosciences).

**Autophagy staining and confocal laser scanning microscopy**
OA chondrocytes with isolated mitochondria were cocultured for 1 day. For confocal staining of LC3 and p62, LAMP1 cells were plated in four-well chamber slides, washed with PBS, fixed in 4% paraformaldehyde, washed with PBS, and blocked with 10% normal goat serum for 30 min. The cells were stained at 4°C overnight with anti-LC3 (ab48394, Abcam), anti-LAMP1 (sc-20011, Santa Cruz Biotechnology, CA), and anti-p62 (ab56416, Abcam) antibodies. The primary antibody was detected using a phycoerythrin-conjugated antirabbit IgG secondary antibody for 2 h at room temperature, and nuclei were stained with DAPI (D3571, Invitrogen). Stained cells were analyzed using a confocal microscope (LSM 510 Meta; Zeiss). The expression of LC3, p62, and LAMP1 was estimated by comparing the mean fluorescence intensity using LSM 510 Meta.

**Western blotting**

The protein levels of LAMP1 (sc-20011, Santa Cruz), p62 (ab56416, Abcam), LC3 (ab48394, Abcam), phosphor MLKL (ab184718, Abcam), and GAPDH (ab181602, Abcam) were measured by western blotting (SNAP i.d. Protein Detection System, Merck Millipore, Danvers, MD). Cells were incubated in six-well plates with IL-1β (20 ng/mL) in the presence or absence of mitochondria (5 μg) for 24 h, and mitochondrial and whole-cell lysates were prepared. Protein concentration was measured by BCA assay (23235, Thermo), and samples were separated on a 4–12% sodium dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham Pharmacia, Uppsala, Sweden). Primary antibodies to LC3, p62, LAMP1, pMLKL, and GAPDH were diluted in 0.1% skim milk in Tris-buffered saline Tween-20 and incubated for 15 min at room temperature. The membrane was washed and incubated with horseradish peroxidase-conjugated secondary antibody for 10 min at room temperature. Band density was estimated by image-capture densitometry.

**Reverse transcription-quantitative real-time PCR**

mRNA was extracted using TRIzol (Molecular Research Center, Cincinnati, OH). cDNA was synthesized using the Superscript Reverse Transcription system (Takara, Shiga, Japan), and qPCR was performed using LightCycler FastStart DNA Master SYBR Green I (Takara) following the manufacturer’s instructions. Expression values were normalized to that of β-actin. Primer sequences are listed in Supplementary Table 1.

**Statistical analysis**

Results are means ± standard error of the mean (SEM). Data were analyzed by Student’s t-test or Mann–Whitney U-test using Prism 5 software (GraphPad, La Jolla, CA). P < 0.05 (two-tailed) was considered indicative of significance.

**Results**

**Isolation of mitochondria**
11.68 ± 0.68 μg of mitochondria were obtained from 1 × 10^6 of L6 cells (Fig. 1a). Contamination during mitochondrial isolation was confirmed by immunoblotting using Cox4, which is located in the inner mitochondrial membrane (Fig. 1b). Flow cytometry for the mitochondrial marker, NAO, showed that the isolated mitochondria showed 96.7% purity (Fig. 1c). The ATP content of isolated mitochondria was measured using three different amounts of mitochondria (Fig. 1d).

**Attenuation of OA progression by mitochondrial transplantation**

The clinical phenotypes, including paw withdrawal latency (PWL), the paw withdrawal threshold (PWT), and weight-bearing, were improved in mitochondrial-injected rats compared to the controls (Fig. 1e, f). Therefore, mitochondrial injection suppresses the progression of OA by suppressing the pain sensation and severity of the OA model. CTX-II is a degradation product of type II collagen, a component of cartilage, and its serum level is increased in severe OA. The CTX-II level was decreased in the mitochondrial transplanted group (Fig. 1g). Histological and micro-CT data showed that destruction of joint and bone loss was improved in the mitochondria-transplanted group. Safranin O staining and micro-CT data showed cartilage destruction and bone loss in the knee joint of the vehicle group, which were improved in the mitochondria-transplantation group (Fig. 1h, i). Micro-CT showed that mitochondrial administration reduces bone damage in the knee joint (Fig. 1j). Bone surface and bone volume were significantly increased in the mitochondria-transplantation group compared to the vehicle group (Fig. 1k).

**Downregulation of proinflammatory cytokines in the knee joint of MIA-induced rat**

The expression of the proinflammatory cytokines IL-1β, TNF-α, MMP-13 (catabolic factor), and p-MLKL (necroptosis marker) was decreased in the mitochondria-transplantation group (Supplementary Fig. 1a, b). Therefore, mitochondrial transplantation ameliorates OA progression by regulating inflammation.

**Improvement of mitochondrial function by mitochondria transfer in rat OA chondrocytes**

We observed mitochondrial swelling and cristae structural changes and a decreased number of mitochondria in chondrocytes of the vehicle group compared to the WT (uninduced OA) and these changes were rescued by mitochondrial transplantation (Fig. 2a, b). Such changes are typically associated with mitochondrial dysfunction and were rescued by mitochondrial transplantation. Depolarization of mitochondrial membrane was observed in the vehicle group and was rescued in the mitochondria-transplantation group (Fig. 2c).

**Improvement of mitochondrial function by mitochondria transfer in OA chondrocytes**

To confirm the intracellular transmission of mitochondria, isolated mitochondria were stained with MitoTracker Deep Red (MTDR) and cocultured with human chondrocytes. MTDR stained mitochondria were transmitted intracellularly at 24 h after coculture with chondrocytes (Fig. 3 a, b). The expression of the OXPHOS complex was measured in chondrocytes after culture with IL-1β (20 ng/mL) for 24 h in the presence or absence of mitochondria. The expression of complexes IV and V was increased in the
mitochondria-transplantation group (Fig. 3c) and the mitochondrial membrane potential was significantly increased (Fig. 3d). We observed mitochondrial swelling, which was rescued by mitochondria transplantation, as in MIA-induced OA rats (Fig. 3e, f).

**Regulation of autophagy by mitochondrial transplantation**

The increased ROS levels in OA impede autophagolysosome progression by inducing mitochondrial and lysosomal dysfunction (18). The ROS level was increased in OA chondrocytes treated with IL-1β and was decreased in the mitochondria-transplantation group (Fig. 4a). The expression of LC-3II (autophagy flux marker) and LAMP1 (lysosome marker) in chondrocytes was significantly increased and decreased, respectively, by IL-1β treatment and was rescued by mitochondrial transplantation (Fig. 4b). These results were confirmed by confocal microscopy and TEM. The colocalization between LC3 and P62 (autophagosome) was increased in the presence of IL-1β, however, the colocalization of LC3-LAMP1 (autophagolysosom3) was increased under the condition of mitochondrial transplantation (Fig. 4c, d). Also, TEM data showed that autophagosome (red arrow) was decreased in the presence of IL-1β, and autophagolysosome (yellow arrow) was increased under the condition of mitochondrial transplantation (Fig. 4e, f). Our data indicate that mitochondrial transplantation improves mitochondrial function through the regulation of autophagy.

**Mitochondrial transfer reduced catabolic and inflammatory cell death markers**

The catabolic factors MMP-1, MMP-3, and MMP-13 were decreased by mitochondrial transplantation (Fig. 5a). Necroptosis of OA chondrocytes was increased by IL-1β and improved by mitochondrial transplantation (Fig. 5b). Also, the expression of the inflammatory cell death marker, p-MLKL, was decreased by mitochondrial transplantation (Fig. 5c). The mRNA levels of col2a1 and aggrecan, which are components of cartilage, were increased by mitochondrial transplantation (Fig. 5d).

**Effect of xenogeneic mitochondrial transplantation on MIA-induced OA**

The PWL, PWT, and weight-bearing were significantly improved in the mitochondria-transplantation group compared with the control group (Fig. 6a, b). Histopathological and micro-CT data showed the therapeutic effect of mitochondrial transplantation in cartilage destruction and bone loss in the knee joint (Fig. 6c, d). Also, the expression of IL-1β, TNF-α, MMP-13, and p-MLKL was decreased in the mitochondria-transplantation group (Fig. 6e).

**Discussion**

This is the first report of a protective effect of exogenous mitochondrial transplantation on OA. We aimed to ameliorate OA development and progression by mitochondrial transplantation *in vivo* and *in vitro*. We obtained mitochondria from L6 cells and administered them to OA animals as well as OA chondrocytes. We evaluated OA progression and expression of OA-related factors.
MMP-induced cartilage destruction is a hallmark of OA (27–29). MMP-13 targets cartilage for degradation and its expression level is affected by IL-1β and TNF-α (30–32). The MCP-1-CCR2 axis plays a crucial role in the development and progression of osteoarthritis (33, 34). Phosphorylation of MLKL by the protein kinase RIPK3 induces necroptosis (35, 36) and OA progression (37, 38). Clinical phenotypes such as pain management, cartilage destruction, and bone resorption were in support of mitochondrial transplantation. Also, mitochondrial transplantation decreases the levels of IL-1β, TNF-α, MCP-1, MMP13, and phosphor-MLKL.

Mitochondrial dysfunction occurs during OA progression (8, 9) and manifests as decreased ATP synthesis, decreased membrane potential, and increased oxidative stress, resulting in cartilage destruction (39). Mitochondrial dysfunction induces IL-1β release and leads to inflammation in chondrocytes by decreasing respiratory chain complex activity (6, 40). Mitochondrial morphology and structure are impaired in OA chondrocytes (8, 15). Mitochondria are swollen and mitochondrial cristae are decreased in OA chondrocytes. In this study, the impaired mitochondrial morphology decreased mitochondrial membrane potential, and expression of respiratory chain complexes was improved in mitochondrial transferred chondrocytes. Therefore, mitochondrial transplantation ameliorates OA progression by improving mitochondrial function.

Autophagy is the self-degradative cellular and molecular mechanism that removes dysfunctional or unnecessary proteins and organelles (17). There are three types of autophagy: macro-autophagy, micro-autophagy, and chaperone-mediated autophagy, which promote proteolytic degradation by the lysosome (41). Impaired autophagy is related to disease development and progression (42, 43). Autophagy is impaired in OA animal models (44) and OA patients (45). ROS is essential for autophagy and regulates the activity of ATG4, a protease critical for autophagy (46). Increased ROS inhibits ATG4 activity, suppressing autophagic influx. There is a relationship between autophagy and apoptosis, however, little is known of the relationship between autophagy and necroptosis. In this study, necroptosis was decreased, and impaired autophagy was improved by mitochondrial transplantation by regulating ROS activity.

Mitochondrial transplantation, even of autologous mitochondria, can induce an immune response (47). By contrast, another group found no inflammation after mitochondrial transplantation (48). In this study, there was no inflammation or allogeneic or xenogeneic transplantation. Also, there was no immune response after mitochondrial transplantation, but this needs to be verified by further studies.

The development of OA is accelerated by joint deformity and instability. Intraarticular ligaments promote static stability of joints and muscles and tendons around joints provide dynamic stability. Therefore, mitochondrial transplantation to muscle and tendon around joints can strengthen muscle and protect joints from OA.

Mitochondrial transplantation was first applied for ischemic disease. Mitochondrial transplantation protects and promotes the regeneration of chondrocytes. Also, compared to cellular therapeutics, mitochondrial transplantation maintains cellular homeostasis and regulates inflammation and cell death.
In this study, we demonstrate the therapeutic potential of mitochondrial transplantation for OA. OA development and progression were ameliorated by mitochondrial transplantation by regulating inflammatory and catabolic factors. Mitochondrial transplantation improved mitochondrial dysfunction and activated autophagy by inhibiting ROS activity.

Conclusions

Mitochondrial transplantation ameliorated OA progression, which is caused by mitochondrial dysfunction. Our findings indicate the therapeutic potential of mitochondrial transplantation for OA.

Declarations

Ethics approval and consent to participate

The experimental procedures were reviewed and approved by the Catholic University Animal Care and Ethics Committee (Approval No. 2021-0078-01). OA patient were recruited from the Orthopedic Surgery, Uijeongbu St. Mary's Hospital, Seoul, Korea (IRB No. UC21TISI0069).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and anlayed during the current study are available from corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI20C1496).

Authors’ contributions

A.R.L., S.H.P., S.J.K., and M.L.C. were involved in conception and design of study. A.R.L., J.S.W., S.Y.L., H.S.N., K.H.C., Y.S.L., J.S.L., and S.A.K. were involved in acquisition of data. A.R.L., J.S.W., and S.Y.L. were involved in analysis and interpretation of data. A.R.L., J.S.W., S.J.K., and M.L.C. were involved in manuscript drafting. All authors were involved in revising manuscript critically for important intellectual content, and all authors approved the final version to be published. M.L.C. had full access to all of the
data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Acknowledgments**

Not applicable.

**References**


43. Hsu HC, Chen YH, Lin TS, Shen CY, Hsieh SC. Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Biochim Biophys Acta Mol Basis


Figures
Figure 1

Attenuation of osteoarthritis by mitochondrial transplantation. (a) Isolated mitochondria from NIH3T3 and L6 cells. (b) Representative immunoblot of tubulin and COX4 in cytosolic and mitochondrial fractions. (c) Representative FACS plot of NAO staining. Averaged percentage of NAO-positive isolated mitochondria. (d) Average ATP content of isolated mitochondria. MIA-induced OA rats were observed and evaluated for 29 days (n = 5 animals per group). The mitochondrial injection was performed intra-articularly twice weekly. Kinetics of PWL, PWT (e), and weight-bearing (f). (g) The average amount of CTX-II in serum of each group. (h) Representative images of Safranin O-stained cartilage. Scale bar = 100 μm. (i) Average total Mankin score (left) and OARIS score (right). (j) Representative micro CT images of bone. (k) Percentage of bone surface (left) and BV: TV ratio (right). Data are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).
Figure 2

Improvement of mitochondrial function in chondrocytes of OA rats by mitochondrial transplantation. Chondrocytes were isolated from MIA-induced OA rats. (a) Transmission electron microscopy images of chondrocytes from MIA-induced OA rats. Red arrow, mitochondria. Scale bar, 2 μm (upper panels) and 0.5 μm (lower panels). (b) Number of mitochondria (left) and average mitochondrial diameter (right). (c) Mitochondrial membrane potential by JC-1 staining. Data are means ± SEM (*p < 0.05, **p < 0.01).
Figure 3

Improvement of mitochondrial function in human OA chondrocytes by mitochondrial transplantation. MTDR-stained mitochondria were transferred into human chondrocytes. (a) Representative FACS plots of percentages of MTDR-positive cells. Average MTDR-positive cells. (b) Representative images of MTDR (red) and DAPI (blue) positive cells. Average MFI of MTDR. Scale bar = 20 μm. (c) mtOXPHOS Complex genes were determined by RT-qPCR in OA chondrocytes incubated in the presence or absence of IL-1β (20 ng/mL) and mitochondria (5 μg) for 24 h. Average transcript levels of complex I, III, IV, and V. (d) Mitochondrial membrane potential analyzed by JC-1 staining. (e) Transmission electron micrographs of chondrocytes from OA patients. Arrowheads, mitochondria. Scale: 2 μm (upper panels), 0.5 μm (lower panels). (f) The average number of mitochondria (left) and mitochondrial diameter (right). Data are means ± SEM (*p < 0.05, **p < 0.01).
Figure 4

Regulation of autophagy activity by mitochondrial transfer. Human OA chondrocytes were cultured with mitochondria (5 μg) in the presence or absence of IL-1β (20 ng/mL) for 24 h. (a) Mitochondrial ROS was measured using MitoSOX dye and flow cytometry. (b) Representative immunoblots of LC3, p62, and LAMP1. Average LC-3I and LC-3II (left), p62 and GAPDH (middle), and LAMP1 and GAPDH (right) ratio. (c) Confocal micrographs show colocalization of p62 (FITC) and LC3 (APC), and LAMP1 (PE) and LC3 (APC) for autophagosome and autophagolysosome, respectively. Scale bar = 20 μm. (d) Percentages of cells with autophagosomes and autophagolysosomes. (e) Autophagy was analyzed by TEM. Red arrows, autophagosomes; yellow arrows, autophagolysosomes. Scale bar = 2 μm (upper panels), 0.5 μm (lower panels). (f) Percentages of cells with autophagosomes and autophagolysosomes. Data are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).
Figure 5

Expression of cell death and cartilage regulatory markers following mitochondria administration. Human OA chondrocytes were cultured with mitochondria (5 μg) in the presence or absence of IL-1β (20 ng/mL) for 24 h. (a) mRNA levels of catabolic factors. (b) Necroptosis analysis by annexin V/PI staining. (c) pMLKL expression in OA chondrocytes analyzed by western blotting. (d) mRNA levels of chondrogenesis markers in OA chondrocytes. Data are means ± SEM (*p < 0.05).
Figure 6

Mitochondrial transplantation from OA patient muscle tissue in MIA-induced rat joint. MIA-induced OA rats were evaluated for 21 days (n = 3 animals per group). Intra-articular mitochondria injection was performed twice weekly. Kinetics of PWL, PWT (a), and weight-bearing (b). (c) Representative images of Safranin O-stained cartilage. Average total Mankin score (left) and OARIS score (right). (d) Representative micro-CT images of bone. Percentage of bone surface (left) and BV: TV ratio (right). (e) IL-1β, TNF-α, MCP-1, MMP-13, and p-MLKL expression determined immunohistochemically in the synovium of MIA-induced OA rats. Data are means ± SEM (*p < 0.05, **p < 0.01).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- LeeetalSuppleInfo.docx